Emerging evidence reveals a clinically significant rebound effect following the discontinuation of glucagon-like peptide-1 ...

What else is there to share? As it happens, quite a lot. Last time I spoke about the diagnosis of Young Onset Parkinson’s disease (YOPD), how this presented several day-to-day challenges from securing ...